The cardiolipin-targeting peptide SS-31/elamipretide became the first approved therapy for Barth syndrome, based on >45% improvement in knee extensor muscle strength in the Phase 2 TAZPOWER trial — a landmark for the whole mitochondrial-peptide class.
Read source →Mitrix Bio is manufacturing donor mitochondria in bioreactors and infusing them into paying patients at Right to Try clinics in Texas, California, and Florida — including a 91-year-old physicist as one of its first two patients. No peer-reviewed efficacy data exists yet. Included as a development worth watching, not a recommendation — this is an unregulated, direct-to-consumer offering with an N of 2.
Read source →